Who are VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comparator: losartan +/- HCTZ, Azilsartan medoxomil and hydrochlorothiazide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/valsartan-valsartan-hydrochlorothiazide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE — Competitive Intelligence Brief

VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE (VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker (ARB) + thiazide diuretic. Area: Cardiovascular.

marketed Angiotensin II receptor blocker (ARB) + thiazide diuretic AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter (NCC) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE (VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE) — Novartis. Valsartan blocks angiotensin II receptors to relax blood vessels and lower blood pressure; the combination with hydrochlorothiazide adds a diuretic to enhance sodium and water excretion.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE TARGET	VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE	Novartis	marketed	Angiotensin II receptor blocker (ARB) + thiazide diuretic	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter (NCC)
Comparator: losartan +/- HCTZ	Comparator: losartan +/- HCTZ	Organon and Co	phase 3	Angiotensin II receptor blocker (ARB) + thiazide diuretic combination	AT1 angiotensin II receptor; sodium-chloride cotransporter (HCTZ)
Azilsartan medoxomil and hydrochlorothiazide	Azilsartan medoxomil and hydrochlorothiazide	Takeda	phase 3	Angiotensin II receptor blocker (ARB) + thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker (ARB) + thiazide diuretic class)

Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE — Competitive Intelligence Brief. https://druglandscape.com/ci/valsartan-valsartan-hydrochlorothiazide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab